De Novo Myelodysplastic Syndrome clinical trials at UCSD
1 in progress, 1 open to new patients

  • Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

    open to eligible people ages 18 years and up

    This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

    San Diego, California and other locations

© The Regents of the University of California